Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR0602 in Advanced Antigen-Rich Solid Tumors
NCT05592626Phase 2Recruiting
- Sponsor
- Marengo Therapeutics
- Start
- Jan 2023
- Primary completion
- Sep 2027
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 2, open-label trial of invikafusp alfa in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (2 arms), sponsored by Marengo Therapeutics. Primary endpoints: Dose-limiting Toxicities at 28 days, Adverse Events and Serious Adverse Events up to 3 years and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
invikafusp alfa
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05592626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05592626.